Overview

The Efficacy and Safety of the Combination Therapy of Daratumumab, Cabozantinib, Pomalidomide, and Dexamethasone (D-KPd) in the Treatment of High-risk First-time Relapsed or Primary Refractory MM Patients

Status:
NOT_YET_RECRUITING
Trial end date:
2026-09-30
Target enrollment:
Participant gender:
Summary
This study is a prospective, single center, single arm phase II clinical trial. The study population consists of patients who have received treatment with VRd or VRd lite regimens for 2-8 courses in the past and have achieved therapeutic effects, but have progressed during treatment (primary refractory), experienced clinical recurrence for the first time after treatment, or progressed or recurred after the first transplant (without entering maintenance therapy). 72 patients are planned to be enrolled and receive 4 courses of induction therapy with D-KPd regimen for the first efficacy evaluation. For patients with SD, if the patient has PR and is suitable for ASCT, ASCT treatment will be given. For patients with\Phase: NA
Details
Lead Sponsor:
The First Affiliated Hospital of Soochow University
Treatments:
daratumumab
Dexamethasone
pomalidomide